ARTICLE | Company News
Corvas, Dyax cancer deal
September 20, 2001 7:00 AM UTC
CVAS and DYAX partnered to research, develop and market serine protease inhibitors for cancer. DYAX will use its phage display technology to identify small proteins, peptides and antibodies that bind ...